FOR IN VITRO AND PRE-CLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE
Growth Hormone

Tesamorelin 5mg

5mg GHRH analogue research compound

From€39.00
In Stock · Ships within 48h
Reviews coming soonBe among the first to share your research experience.
Download Certificate of Analysis
  • EU Dispatch
  • CoA Included — Every Batch
  • Discreet Packaging
Purity≥98% HPLC
FormLyophilised Powder
Storage2–8°C
OriginEuropean Stock
DispatchWithin 48h
SKUUL-TES-5MG
≥98% PureHPLC verified
HPLC TestedDual identity check
EU DispatchShips within 48h
CoA Incl.Every batch
Research Profile

Why Tesamorelin Fascinates Researchers

Tesamorelin is a synthetic analogue of endogenous growth hormone-releasing hormone (GHRH), in which the native forty-four-residue peptide is conjugated at its N-terminus to a trans-3-hexenoic acid moiety. This structural modification dramatically extends the peptide's plasma half-life relative to native GHRH while preserving full biological activity at the pituitary GHRH receptor — making it the only GHRH analogue that has undergone rigorous Phase 3 clinical evaluation.

The GHRH-GH-IGF-1 Axis

Growth hormone-releasing hormone (GHRH) is secreted by hypothalamic neurons in pulses and acts on pituitary somatotroph cells via the GHRH receptor (GHRHR) — a G protein-coupled receptor coupled to adenylyl cyclase. The resulting increase in intracellular cAMP stimulates both GH synthesis and pulsatile GH secretion. GH then acts in liver to stimulate IGF-1 synthesis, while also exerting direct lipolytic effects in adipose tissue. The net metabolic consequences of pulsatile GH secretion include enhanced fat utilisation (particularly visceral adipose) and support for lean body composition — a physiology highly sensitive to the somatopause, the progressive decline in GH secretory amplitude that characterises normal ageing.

Pharmacological Profile & GHRH Receptor Pharmacology

The trans-3-hexenoic acid modification at the N-terminus of tesamorelin prevents cleavage by dipeptidyl peptidase-4 (DPP-4), the enzyme responsible for the rapid inactivation of native GHRH (plasma half-life approximately 7 minutes). This pharmacokinetic advantage, combined with the preservation of native receptor binding geometry, results in a compound that can sustain pituitary GHRHR activation over experimentally relevant timeframes. The pharmacological consequence is amplification of endogenous pulsatile GH secretion rather than replacement — an important distinction from exogenous GH administration, as the hypothalamic-pituitary feedback axis remains intact.

Clinical Research Data

Tesamorelin is the only GHRH analogue to have completed Phase 3 randomised controlled trials. Falutz and colleagues reported significant reductions in visceral adipose tissue (measured by CT) in HIV-associated lipodystrophy patients, leading to FDA approval in 2010 for this indication under the brand Egrifta. The clinical research data provide uniquely detailed pharmacodynamic information for a GHRH analogue, including dose-response characteristics, pituitary GH secretory dynamics, and tissue-specific metabolic consequences of GHRH receptor activation in humans.

This content is for informational purposes only and reflects the state of preclinical and clinical research. It does not constitute medical advice, endorsement of human use, or therapeutic claims of any kind.

Manufacturing Standards

Our Quality Commitment

HPLC Verified

Purity confirmed by High-Performance Liquid Chromatography at an accredited EU laboratory.

≥98% Purity

Every batch meets or exceeds 98% purity. CoA available for verification before dispatch.

Batch Traceability

Each vial is traceable to its synthesis batch, testing date, and analytical records.

Cold Chain Storage

European stock stored at optimal temperature from synthesis to dispatch.

48h EU Dispatch

Orders ship from EU stock within 48 hours with discrete, temperature-appropriate packaging.

CoA Included

Certificate of Analysis issued for every batch, available for download on request.

Download CoA for Tesamorelin 5mg
Peer-Reviewed Literature

Key Scientific Studies

Peer-reviewed research supporting Tesamorelin investigation.

[01]
Falutz J, Allas S, Blot K, et al. (2007) — New England Journal of Medicine

“Metabolic effects of a growth hormone-releasing factor in patients with HIV”

Phase 3 randomised controlled trial of tesamorelin in HIV-positive patients with lipodystrophy. Administration produced significant reductions in visceral adipose tissue (mean −15.2%), improvements in waist circumference, and favourable changes in lipid profiles compared to placebo, with GH and IGF-1 levels increasing within normal physiological ranges — demonstrating the capacity of GHRH receptor activation to modulate adipose distribution in human subjects.

View on PubMed
[02]
Falutz J, Mamputu JC, Potvin D, et al. (2010) — AIDS

“Effects of tesamorelin (TH9507), a growth hormone-releasing factor analogue, in HIV-infected patients with excess abdominal fat”

Extension study examining the long-term safety and efficacy of tesamorelin over 52 weeks. Sustained reductions in visceral adipose tissue were maintained with continued administration; discontinuation resulted in progressive return toward baseline, confirming the administration-dependent nature of the effect and providing important pharmacodynamic insights for GHRH axis research.

View on PubMed
[03]
Stanley TL, Falutz J, Marsolais C, et al. (2012) — Journal of Clinical Endocrinology & Metabolism

“Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin”

Secondary analysis of Phase 3 tesamorelin trial data examining the metabolic consequences of visceral adipose tissue reduction. Decreases in visceral fat were associated with improvements in triglycerides, HDL cholesterol, and estimated cardiovascular risk, providing mechanistic context for the relationship between GHRH axis activity, visceral adiposity, and cardiometabolic risk markers.

View on PubMed

All studies referenced are independent third-party research. UNIK LAB makes no claims regarding the therapeutic efficacy of any compound and does not represent or endorse the conclusions of cited studies. All referenced research was conducted under controlled laboratory or clinical conditions; results may not be predictive of effects in other experimental contexts.

Common Questions

Research FAQ

Answers to the most frequently asked questions about Tesamorelin.

Same Category

Similar Compounds

Other Growth Hormone research compounds from our catalogue.

Your Longevity Research Guide Awaits

Subscribe to receive new compound profiles, CoA updates, and curated research digests — delivered directly to your inbox.